Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 6;12(11):e026890.
doi: 10.1161/JAHA.122.026890. Epub 2023 Jun 1.

Exercise Capacity and Ventilatory Efficiency in Patients With Pulmonary Arterial Hypertension

Affiliations

Exercise Capacity and Ventilatory Efficiency in Patients With Pulmonary Arterial Hypertension

Kazuki Tobita et al. J Am Heart Assoc. .

Abstract

Background The symptom for identification of pulmonary arterial hypertension (PAH) is dyspnea on exertion, with a concomitant decrease in exercise capacity. Even patients with hemodynamically improved PAH may have impaired exercise tolerance; however, the effect of central and peripheral factors on exercise tolerance remains unclear. We explored the factors contributing to exercise capacity and ventilatory efficiency in patients with hemodynamically normalized PAH after medical treatment. Methods and Results In total, 82 patients with PAH (age: median 46 [interquartile range, 39-51] years; male:female, 23:59) and mean pulmonary arterial pressure ≤30 mm Hg at rest were enrolled. The exercise capacity, indicated by the 6-minute walk distance and peak oxygen consumption, and the ventilatory efficiency, indicated by the minute ventilation versus carbon dioxide output slope, were assessed using cardiopulmonary exercise testing with a right heart catheter. The mean pulmonary arterial pressure was 21 (17-25) mm Hg, and the 6-minute walk distance was 530 (458-565) m, whereas the peak oxygen consumption was 18.8 (14.8-21.6) mLꞏmin-1ꞏkg-1. The multivariate model that best predicted 6-minute walk distance included peak arterial mixed venous oxygen content difference (β=0.46, P<0.001), whereas the best peak oxygen consumption predictors included peak cardiac output (β=0.72, P<0.001), peak arterial mixed venous oxygen content difference (β=0.56, P<0.001), and resting mean pulmonary arterial pressure (β=-0.25, P=0.026). The parameter that best predicted minute ventilation versus carbon dioxide output slope was the resting mean pulmonary arterial pressure (β=0.35, P=0.041). Quadriceps muscle strength was moderately correlated with exercise capacity (6-minute walk distance; ρ=0.57, P<0.001; peak oxygen consumption: ρ=0.56, P<0.001) and weakly correlated with ventilatory efficiency (ρ=-0.32, P=0.007). Conclusions Central and peripheral factors are closely related to impaired exercise tolerance in patients with hemodynamically normalized PAH.

Keywords: 6‐minute walk distance; exercise capacity; hemodynamics; muscle strength; pulmonary arterial hypertension; ventilatory efficiency.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Correlation between quadriceps muscle strength and peak C(a‐v)O2.
The quadriceps muscle strength was positively correlated with peak C(a‐v)O2. C(a‐v)O2 indicates arterial mixed venous oxygen content difference.
Figure 2
Figure 2. Correlations between quadriceps muscle strength and (A) 6‐MWD, (B) peak VO2, and (C) ventilatory efficiency (VE vs VCO2 slope).
The 6‐MWD and peak VO2 were positively correlated with quadriceps muscle strength, and the VE vs VCO2 slope was negatively correlated with quadriceps muscle strength. 6‐MWD indicates 6‐minute walk distance; peak VO2, peak oxygen consumption; VCO2, carbon dioxide output; and VE, minute ventilation.
Figure 3
Figure 3. Correlation between quadriceps muscle strength and resting mean PAP.
The quadriceps muscle strength was negatively correlated with resting mean PAP. PAP indicates pulmonary artery pressure.

Similar articles

Cited by

References

    1. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:53. doi: 10.1183/13993003.01887-2018 - DOI - PMC - PubMed
    1. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal‐oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858–863. doi: 10.1183/09031936.05.00075305 - DOI - PubMed
    1. Malenfant S, Lebret M, Breton‐Gagnon É, Potus F, Paulin R, Bonnet S, Provencher S. Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms. Eur Respir Rev. 2021;30:30. doi: 10.1183/16000617.0284-2020 - DOI - PMC - PubMed
    1. Tobita K, Goda A, Nishida Y, Takeuchi K, Kikuchi H, Inami T, Kohno T, Yamada S, Soejima K, Satoh T. Factors contributing to exercise capacity in chronic thromboembolic pulmonary hypertension with near‐normal hemodynamics. J Heart Lung Transplant. 2021;40:677–686. doi: 10.1016/j.healun.2021.03.003 - DOI - PubMed
    1. Batt J, Ahmed SS, Correa J, Bain A, Granton J. Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2014;50:74–86. doi: 10.1165/rcmb.2012-0506OC - DOI - PubMed